– Ludman SW, Boyle RJ. Stinging insect allergy: current perspectives on venom immunotherapy. J Asthma Allergy. 2015;8:75–86.
– Bilò MB, Cichocka-Jarosz E, Pumphrey R, Oude-Elberink JN, Lange J, et al. Self-medication of anaphylactic reactions due to Hymenoptera stings-an EAACI Task Force Consensus Statement. Allergy. 2016;
71(7):931–43.
– Köhler J, Blank S, Müller S, Bantleon F, Frick M, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol. 2014;133(5):1383–9.
– Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Seitz MJ, et al. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PLoS One. 2013;8(5):e63233.
– Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De Ferrari L, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract. 2013;1(5):474–8.
1 Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy. 2009;39(10):1467–76.
2 de Haro L, Labadie M, Chanseau P, Cabot C, Blanc-Brisset I, et al. Medical consequences of the Asian black hornet (Vespa velutina) invasion in Southwestern France. Toxicon. 2010;55(2–3):650–2.
3 Hoffman DR, Jacobson RS. Allergens in Hymenoptera venom XII: how much protein is in a sting? Ann Allergy. 1984;52:276–8.
4 Ludman SW, Boyle RJ. Stinging insect allergy: current perspectives on venom immunotherapy. J Asthma Allergy. 2015;8:75–86.
5 Biló BM1, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN, et al. Diagnosis of Hymenoptera venom allergy. EAACI Interest Group on Insect Venom Hypersensitivity. Allergy. 2005;60(11):1339–49.
6 Ertoy Karagol HI, Bakirtas A, Yilmaz O, Topal E, Arga M, et al. Long-term follow-up of re-sting reactions in children with moderate to severe venom hypersensitivity. Eur J Pediatr. 2015;174(7):891–6.
7 Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase – a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124(5):1047–54.
8 Haeberli G, Brönnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003;33(9):1216–20.
9 Niedoszytko M, Bonadonna P, Oude Elberink JN, Golden DB. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients. Immunol Allergy Clin North Am. 2014;34(2):365–81.
10 Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63(2):226–32.
11 Simons FE, Ebisawa M, Sanchez-Borges M, Thong BY, Worm M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):32.
12 Bilò MB, Cichocka-Jarosz E, Pumphrey R, Oude-Elberink JN, Lange J, et al. Self-medication of anaphylactic reactions due to Hymenoptera stings-an EAACI Task Force Consensus Statement. Allergy. 2016;71(7):931–43.
13 Jörg L, Steiner U, Fricker M, Helbling A. Der allergische Notfall: Adrenalin das Mittel der Wahl bei der Anaphylaxie. Z Allg Med. 2013;89(12):516–21.
14 Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A.
IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from crossreaction in venom allergy. Allergy. 2012;67(8):1069–73.
15 Hemmer W, Focke M, Kolarich D, Wilson IB, Altmann F, et al. Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy. J Allergy Clin Immunol. 2001 Dec;108(6):1045–52.
16 Eberlein B, Krischan L, Darsow U, Ollert M, Ring J. Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants. J Allergy Clin Immunol. 2012;130(1):155–61.
17 Köhler J, Blank S, Müller S, Bantleon F, Frick M, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol. 2014;133(5):1383–9.
18 Sturm GJ, Böhm E, Trummer M, Weiglhofer I, Heinemann A, et al. The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study. Allergy. 2004;59(10):1110–7.
19 Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Seitz MJ, et al. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PLoS One. 2013;8(5):e63233.
20 Toletone A, Voltolini S, Passalacqua G, Dini G, Bignardi D, et al. Hymenoptera venom allergy in outdoor workers: occupational exposure, clinical features and effects of allergen immunotherapy. Hum Vaccin Immunother. 2016;7:0. [Epub ahead of print].
21 Kosnik M, Korosec P. Venom immunotherapy: clinical efficacy, safety and contraindications. Expert Rev Clin Immunol. 2015;11(8):877–84.
22 Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol. 2008;100(2):162–5.
23 Bonadonna P, Gonzalez-de-Olano D, Zanotti R, Riccio A, De Ferrari L, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract. 2013;1(5):474–8.
24 Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U. EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005;60(12):1459–70.
25 Golden DB. Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol. 2010;10(4):337–41.
26 Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, et al. Clinical contraindications to allergen immunotherapy:
an EAACI position paper. Allergy. 2015;70(8):897–909.
27 Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective. Ann Allergy Asthma Immunol. 2015;114(5):411–6
28 Linneberg A, Jacobsen RK, Jespersen L, Abildstrøm SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol. 2012;129(2):413–9.
29 Patriarca G, Nucera E, Roncallo C, Aruanno A, Lombardo C, et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol. 2008;21(3):669–77.
30 Martínez-Gómez JM, Johansen P, Erdmann I, Senti G, Crameri R, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150(1):59–65.
31 Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101:747–54.